Simcere Pharmaceutical Group Limited
SMHGF
$0.6697
-$0.0641-8.74%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 214.98M | 216.84M | 223.57M | 222.87M | 241.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.98M | 216.84M | 223.57M | 222.87M | 241.30M |
| Cost of Revenue | 44.99M | 45.38M | 55.79M | 55.61M | 58.54M |
| Gross Profit | 169.99M | 171.46M | 167.78M | 167.26M | 182.76M |
| SG&A Expenses | 95.60M | 96.43M | 93.61M | 93.32M | 107.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.94M | -4.98M | -4.72M | -4.71M | -5.46M |
| Total Operating Expenses | 174.74M | 176.26M | 199.20M | 198.57M | 215.76M |
| Operating Income | 40.23M | 40.58M | 24.37M | 24.30M | 25.54M |
| Income Before Tax | 34.16M | 34.45M | -109.77M | -109.43M | 165.85M |
| Income Tax Expenses | 2.63M | 2.65M | -1.75M | -1.74M | 3.66M |
| Earnings from Continuing Operations | 31.53M | 31.80M | -108.02M | -107.68M | 162.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 0.00 | 57.90K |
| Net Income | 31.53M | 31.80M | -108.02M | -107.68M | 162.24M |
| EBIT | 40.23M | 40.58M | 24.37M | 24.30M | 25.54M |
| EBITDA | 47.72M | 48.13M | 31.66M | 31.56M | 33.32M |
| EPS Basic | 0.01 | 0.01 | -0.04 | -0.04 | 0.06 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.01 | 0.01 | -0.04 | -0.04 | 0.06 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 2.55B | 2.55B | 2.60B | 2.60B | 2.62B |
| Average Diluted Shares Outstanding | 2.55B | 2.55B | 2.60B | 2.60B | 2.63B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -26.87% | -26.87% | -- |
